Skip to content

Topography-Guided Customized PRK Versus Q-value Adjusted PRK in Correction of Myopia With or Without Astigmatism

Topography-Guided Customized PRK (Photorefractive Keratectomy) Versus Q-value Adjusted PRK in Correction of Myopia With or Without Astigmatism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03291873
Enrollment
104
Registered
2017-09-25
Start date
2017-10-25
Completion date
2019-06-25
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

This study will include patients who will undergo PRK in both eyes, for each patient each eye will be randomly allocated to one of 2 procedures: topography-guided ablation in one eye (group I) and Q-factor customized ablation in the other eye (group II). Alcon/Wavelight Light Laser Technolo¬gie (GmbH, Erlangen, Germany) will be used for photoablation. The wavelight Topolyzer (Wavelight AG, Erlan¬gen, Germany)and CSO Sirius scheimpflug camera combined with Placido corneal topography (CSO, Florence,Italy) will be used before and 1, 3 and 6 months after PRK. Refrac¬tive visual outcomes and corneal aberration changes will be compared between the two treatment modalities.

Interventions

PROCEDUREPRK

PRK using Alcon-Wavelight Excimer Laser EX 500

Sponsors

Kasr El Aini Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age more than 18 years * Myopia with up to -6.5 D with or without astigmatism up to -4.75 D

Exclusion criteria

* anterior segment abnormalities (ie, cataracts, corneal scarring) * basement membrane disease * history of recurrent corneal erosions * Schirmer's test less than 5 mm * established or forme fruste keratoconus * macular or retinal disease * current use of immunosuppressive therapy * autoimmune disease * pregnancy, and lactation

Design outcomes

Primary

MeasureTime frameDescription
change in Q value1,3 and 6 monthsassessed by topolyzer
change in visual acuity using snellen chart1 , 3 and 6 months postoperative
change in corneal wavefront aberrations1 , 3 and 6 months postoperativeassessed by topolyzer
change in Q value anterior at 6mm RMS, RMS of astigmatism, RMS of coma and RMS of spherical aberrations. Strehl ratio : Qvalue,RMS,strehl ratio by CSO Sirius scheimpflug1,3 and 6monthsby CSO Sirius scheimpflug
change in total RMS1,3 and 6monthsby CSO Sirius scheimpflug
change in strehl ratio1,3 and 6 monthsby CSO scheimpflug
change in Postoperative spherical equivalent depending on manifest refraction after autorefractometer1 , 3 and 6 months postoperative

Secondary

MeasureTime frameDescription
contrast sensitivity6 monthscambridge low contrast sensitivity
predictability6 monthseyes within 1.0 D of emmetropia
safety:ratio of mean preoperative decimal CDVA to mean postoperative decimal CDVA6 monthsratio of mean preoperative decimal CDVA to mean postoperative decimal CDVA
stability6 monthschange of more than 0.5D over
efficacy:ratio of postoperative decimal UDVA to preoperative decimal CDVA6 monthsratio of postoperative decimal UDVA to preoperative decimal CDVA

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026